CAYARRA Trademark

Trademark Overview


On Wednesday, January 27, 2021, a trademark application was filed for CAYARRA with the United States Patent and Trademark Office. The USPTO has given the CAYARRA trademark a serial number of 90492334. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The CAYARRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
cayarra

General Information


Serial Number90492334
Word MarkCAYARRA
Filing DateWednesday, January 27, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 28, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; ; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Saturday, January 30, 2021NEW APPLICATION ENTERED
Thursday, April 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 13, 2021ASSIGNED TO EXAMINER
Friday, August 20, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 8, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 28, 2021PUBLISHED FOR OPPOSITION
Tuesday, September 28, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 26, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Thursday, October 28, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 28, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 28, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 28, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, December 2, 2021TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, December 21, 2021ASSIGNED TO PETITION STAFF
Tuesday, December 21, 2021CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Sunday, February 6, 2022EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, March 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, September 15, 2022SOU TEAS EXTENSION RECEIVED
Thursday, September 15, 2022SOU EXTENSION 1 FILED
Thursday, September 15, 2022SOU EXTENSION 1 GRANTED
Saturday, September 17, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 9, 2023SOU TEAS EXTENSION RECEIVED
Thursday, March 9, 2023SOU EXTENSION 2 FILED
Thursday, March 9, 2023SOU EXTENSION 2 GRANTED
Saturday, March 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, September 16, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 14, 2023SOU TEAS EXTENSION RECEIVED
Thursday, September 14, 2023SOU EXTENSION 3 FILED
Thursday, September 14, 2023SOU EXTENSION 3 GRANTED
Wednesday, March 13, 2024SOU EXTENSION 4 FILED
Wednesday, March 13, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, March 13, 2024SOU EXTENSION 4 GRANTED
Thursday, March 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 5 FILED
Tuesday, August 27, 2024SOU EXTENSION 5 GRANTED